Top

Published in:

01-10-2007 | Topic Paper

Non-invasive markers of ureteropelvic junction obstruction

Authors: Stephane Decramer, Jean-Loup Bascands, Joost P. Schanstra

Published in: World Journal of Urology | Issue 5/2007

Abstract

Non-invasive prognosis of the clinical progression of disease is of high interest, especially in newborn and children. Neonatal ureteropelvic (UPJ) junction obstruction needs close and invasive surveillance to determine the necessity of pyeloplasty. A number of groups have initiated research with the aim to find non-invasive biomarkers for UPJ obstruction. Two different strategies have been followed. One strategy, based on the knowledge obtained in animal models of UPJ obstruction, has identified a number of individual urinary markers of severe UPJ obstruction. Combining these markers might allow prediction of which patients will require surgery and in which patients UPJ obstruction will spontaneously resolve. The other strategy is based on urinary proteomics. In this strategy the entire urinary proteome is probed for a set of biomarkers that correlates with the degree of UPJ obstruction. In subsequent steps, these sets of urinary biomarkers are used for prediction of the clinical evolution of UPJ obstruction patients. This proteomic-based strategy allowed prediction, several months in advance, of the clinical evolution of neonates with UPJ-obstruction. Both strategies will be complementary and will hopefully replace in the near future the invasive follow-up of newborns with UPJ obstruction.

Chang CP, McDill BW, Neilson JR, Joist HE, Epstein JA, Crabtree GR, Chen F (2004) Calcineurin is required in urinary tract mesenchyme for the development of the pyeloureteral peristaltic machinery. J Clin Invest 113:1051–1058PubMedCrossRef

Zhang PL, Peters CA, Rosen S (2000) Ureteropelvic junction obstruction: morphological and clinical studies. Pediatr Nephrol 14:820–826PubMedCrossRef

Bascands JL, Schanstra JP (2005) Obstructive nephropathy: insights from genetically engineered animals. Kidney Int 68:925–937PubMedCrossRef

Nishimura H, Yerkes E, Hohenfellner K, Miyazaki Y, Ma J, Hunley TE, Yoshida H, Ichiki T, Threadgill D, Phillips JA III, Hogan BM, Fogo A, Brock JW III, Inagami T, Ichikawa I (1999) Role of the angiotensin type 2 receptor gene in congenital anomalies of the kidney and urinary tract, CAKUT, of mice and men. Mol Cell 3:1–10PubMedCrossRef

Matsusaka T, Miyazaki Y, Ichikawa I (2002) The renin angiotensin system and kidney development. Annu Rev Physiol 64:551–561PubMedCrossRef

Csaicsich D, Greenbaum LA, Aufricht C (2004) Upper urinary tract: when is obstruction obstruction? Curr Opin Urol 14:213–217PubMedCrossRef

Chevalier RL, Peters CA (2003) Congenital urinary tract obstruction: proceedings of the state-of-the-art strategic planning workshop-national institutes of health, Bethesda, Maryland, USA, 11-12 March 2002. Pediatr Nephrol 18:576–606PubMed

Huang WY, Peters CA, Zurakowski D, Borer JG, Diamond DA, Bauer SB, McLellan DL, Rosen S (2006) Renal biopsy in congenital ureteropelvic junction obstruction: evidence for parenchymal maldevelopment. Kidney Int 69:137–143PubMedCrossRef

Chevalier RL, Thornhill BA, Chang AY (2000) Unilateral ureteral obstruction in neonatal rats leads to renal insufficiency in adulthood. Kidney Int 58:1987–1995PubMedCrossRef

10.

Thornhill BA, Burt LE, Chen C, Forbes MS, Chevalier RL (2005) Variable chronic partial ureteral obstruction in the neonatal rat: a new model of ureteropelvic junction obstruction. Kidney Int 67:42–52PubMedCrossRef

11.

Chevalier RL (2006) Pathogenesis of renal injury in obstructive uropathy. Curr Opin Pediatr 18:153–160PubMedCrossRef

12.

Furness PD III, Maizels M, Han SW, Cohn RA, Cheng EY (1999) Elevated bladder urine concentration of transforming growth factor-beta1 correlates with upper urinary tract obstruction in children. J Urol 162:1033–1036PubMedCrossRef

13.

Grandaliano G, Gesualdo L, Bartoli F, Ranieri E, Monno R, Leggio A, Paradies G, Caldarulo E, Infante B, Schena FP (2000) MCP-1 and EGF renal expression and urine excretion in human congenital obstructive nephropathy. Kidney Int 58:182–192PubMedCrossRef

14.

El-Sherbiny MT, Mousa OM, Shokeir AA, Ghoneim MA (2002) Role of urinary transforming growth factor-beta1 concentration in the diagnosis of upper urinary tract obstruction in children. J Urol 168:1798–1800PubMedCrossRef

15.

Taha MA, Shokeir AA, Osman HG, Abd el-Aziz Ael A, Farahat SE (2007) Diagnosis of ureteropelvic junction obstruction in children: role of endothelin-1 in voided urine. Urology 69:560–564; discussion 564–565PubMedCrossRef

16.

Taha MA, Shokeir AA, Osman HG, Abd El-Aziz Ael A, Farahat SE (2007) Pelvi-ureteric junction obstruction in children: the role of urinary transforming growth factor-beta and epidermal growth factor. BJU Int 99:899–903PubMedCrossRef

17.

Chevalier RL (2006) Obstructive nephropathy: towards biomarker discovery and gene therapy. Nat Clin Pract Nephrol 2:157–168PubMedCrossRef

18.

Valles PG, Pascual L, Manucha W, Carrizo L, Ruttler M (2003) Role of endogenous nitric oxide in unilateral ureteropelvic junction obstruction in children. Kidney Int 63:1104–1115PubMedCrossRef

19.

Liu Y (2006) Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 69:213–217PubMedCrossRef

20.

Kaneto H, Morrissey J, Klahr S (1993) Increased expression of TGF-beta 1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int 44:313–321PubMedCrossRef

21.

Seremetis GM, Maizels M (1996) TGF-beta mRNA expression in the renal pelvis after experimental and clinical ureteropelvic junction obstruction. J Urol 156:261–266PubMedCrossRef

22.

Wright EJ, McCaffrey TA, Robertson AP, Vaughan ED Jr, Felsen D (1996) Chronic unilateral ureteral obstruction is associated with interstitial fibrosis and tubular expression of transforming growth factor-beta. Lab Invest 74:528–537PubMed

23.

Honkanen E, Teppo AM, Tornroth T, Groop PH, Gronhagen-Riska C (1997) Urinary transforming growth factor-beta 1 in membranous glomerulonephritis. Nephrol Dial Transplant 12:2562–2568PubMedCrossRef

24.

Haramaki R, Tamaki K, Fujisawa M, Ikedo H, Haramaki N, Okuda S (2001) Steroid therapy and urinary transforming growth factor-beta1 in IgA nephropathy. Am J Kidney Dis 38:1191–1198PubMed

25.

De Muro P, Faedda R, Fresu P, Masala A, Cigni A, Concas G, Mela MG, Satta A, Carcassi A, Sanna GM, Cherchi GM (2004) Urinary transforming growth factor-beta 1 in various types of nephropathy. Pharmacol Res 49:293–298PubMedCrossRef

26.

Cha DR, Kim IS, Kang YS, Han SY, Han KH, Shin C, Ji YH, Kim NH (2005) Urinary concentration of transforming growth factor-beta-inducible gene-h3 (beta ig-h3) in patients with type 2 diabetes mellitus. Diabet Med 22:14–20PubMedCrossRef

27.

Tsakas S, Goumenos DS (2006) Accurate measurement and clinical significance of urinary transforming growth factor-beta1. Am J Nephrol 26:186–193PubMedCrossRef

28.

Kaneto H, Morrissey J, McCracken R, Reyes A, Klahr S (1994) Enalapril reduces collagen type IV synthesis and expansion of the interstitium in the obstructed rat kidney. Kidney Int 45:1637–1647PubMedCrossRef

29.

Leonard EJ, Yoshimura T (1990) Human monocyte chemoattractant protein-1 (MCP-1). Immunol Today 11:97–101PubMedCrossRef

30.

Diamond JR, Kees-Folts D, Ding G, Frye JE, Restrepo NC (1994) Macrophages, monocyte chemoattractant peptide-1, and TGF-beta 1 in experimental hydronephrosis. Am J Physiol 266:F926–F933PubMed

31.

Wada T, Furuichi K, Sakai N, Iwata Y, Kitagawa K, Ishida Y, Kondo T, Hashimoto H, Ishiwata Y, Mukaida N, Tomosugi N, Matsushima K, Egashira K, Yokoyama H (2004) Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. J Am Soc Nephrol 15:940–948PubMedCrossRef

32.

Grandaliano G, Gesualdo L, Ranieri E, Monno R, Montinaro V, Marra F, Schena FP (1996) Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides: a pathogenetic role in interstitial monocytes recruitment. J Am Soc Nephrol 7:906–913PubMed

33.

Eardley KS, Zehnder D, Quinkler M, Lepenies J, Bates RL, Savage CO, Howie AJ, Adu D, Cockwell P (2006) The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease. Kidney Int 69:1189–1197PubMedCrossRef

34.

Josephson S, Hemsen A (1994) Renal tissue endothelin in long-term complete ureteric obstruction in the young rat. Urol Int 53:57–61PubMedCrossRef

35.

Feldman DL, Mogelesky TC, Chou M, Jeng AY (2000) Enhanced expression of renal endothelin-converting enzyme-1 and endothelin-A-receptor mRNA in rats with interstitial fibrosis following ureter ligation. J Cardiovasc Pharmacol 36:S255–S259PubMedCrossRef

36.

Kelleher JP, Shah V, Godley ML, Wakefield AJ, Gordon I, Ransley PG, Snell ME, Risdon RA (1992) Urinary endothelin (ET1) in complete ureteric obstruction in the miniature pig. Urol Res 20:63–65PubMedCrossRef

37.

Hegarty NJ, Young LS, O'Neill AJ, Watson RW, Fitzpatrick JM (2003) Endothelin in unilateral ureteral obstruction: vascular and cellular effects. J Urol 169:740–744PubMedCrossRef

38.

Storch S, Saggi S, Megyesi J, Price PM, Safirstein R (1992) Ureteral obstruction decreases renal prepro-epidermal growth factor and Tamm-Horsfall expression. Kidney Int 42:89–94PubMedCrossRef

39.

Chung KH, Chevalier RL (1996) Arrested development of the neonatal kidney following chronic ureteral obstruction. J Urol 155:1139–1144PubMedCrossRef

40.

Ranieri E, Gesualdo L, Petrarulo F, Schena FP (1996) Urinary IL-6/EGF ratio: a useful prognostic marker for the progression of renal damage in IgA nephropathy. Kidney Int 50:1990–2001PubMedCrossRef

41.

Thongboonkerd V, Malasit P (2005) Renal and urinary proteomics: current applications and challenges. Proteomics 5:1033–1042PubMedCrossRef

42.

Schaub S, Wilkins J, Weiler T, Sangster K, Rush D, Nickerson P (2004) Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int 65:323–332PubMedCrossRef

43.

Thongboonkerd V, Chutipongtanate S, Kanlaya R (2006) Systematic evaluation of sample preparation methods for gel-based human urinary proteomics: quantity, quality, and variability. J Proteome Res 5:183–191PubMedCrossRef

44.

Traum AZ, Wells MP, Aivado M, Libermann TA, Ramoni MF, Schachter AD (2006) SELDI-TOF MS of quadruplicate urine and serum samples to evaluate changes related to storage conditions. Proteomics 6:1676–1680PubMedCrossRef

45.

Thongboonkerd V, McLeish KR, Arthur JM, Klein JB (2002) Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int 62:1461–1469PubMedCrossRef

46.

Henzel WJ, Watanabe C, Stults JT (2003) Protein identification: the origins of peptide mass fingerprinting. J Am Soc Mass Spectrom 14:931–942PubMedCrossRef

47.

Issaq HJ, Conrads TP, Prieto DA, Tirumalai R, Veenstra TD (2003) SELDI-TOF MS for diagnostic proteomics. Anal Chem 75:148A–155APubMedCrossRef

48.

Woroniecki RP, Orlova TN, Mendelev N, Shatat IF, Hailpern SM, Kaskel FJ, Goligorsky MS, O'Riordan E (2006) Urinary proteome of steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome of childhood. Am J Nephrol 26:258–267PubMedCrossRef

49.

Khurana M, Traum AZ, Aivado M, Wells MP, Guerrero M, Grall F, Libermann TA, Schachter AD (2006) Urine proteomic profiling of pediatric nephrotic syndrome. Pediatr Nephrol 21:1257–1265PubMedCrossRef

50.

Mosley K, Tam FW, Edwards RJ, Crozier J, Pusey CD, Lightstone L (2006) Urinary proteomic profiles distinguish between active and inactive lupus nephritis. Rheumatology (Oxford) 45:1497–1504CrossRef

51.

Clarke W, Silverman BC, Zhang Z, Chan DW, Klein AS, Molmenti EP (2003) Characterization of renal allograft rejection by urinary proteomic analysis. Ann Surg 237:660–664; discussion 664–665PubMedCrossRef

52.

O'Riordan E, Orlova TN, Mei JJ, Butt K, Chander PM, Rahman S, Mya M, Hu R, Momin J, Eng EW, Hampel DJ, Hartman B, Kretzler M, Delaney V, Goligorsky MS (2004) Bioinformatic analysis of the urine proteome of acute allograft rejection. J Am Soc Nephrol 15:3240–3248PubMedCrossRef

53.

Kolch W, Neususs C, Pelzing M, Mischak H (2005) Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom Rev 24:959–977PubMedCrossRef

54.

Decramer S, Wittke S, Mischak H, Zurbig P, Walden M, Bouissou F, Bascands JL, Schanstra JP (2006) Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat Med 12:398–400PubMedCrossRef

55.

Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, Mischak H, Frierson HF (2006) Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 7:230–240PubMedCrossRef

56.

Chertin B, Pollack A, Koulikov D, Rabinowitz R, Hain D, Hadas-Halpren I, Farkas A (2006) Conservative treatment of ureteropelvic junction obstruction in children with antenatal diagnosis of hydronephrosis: lessons learned after 16 years of follow-up. Eur Urol 49:734–738; discussion 739PubMedCrossRef

57.

Eyre D (2002) Collagen of articular cartilage. Arthritis Res 4:30–35PubMedCrossRef

58.

Cochrane AL, Kett MM, Samuel CS, Campanale NV, Anderson WP, Hume DA, Little MH, Bertram JF, Ricardo SD (2005) Renal structural and functional repair in a mouse model of reversal of ureteral obstruction. J Am Soc Nephrol 16:3623–3630PubMedCrossRef

Title: Non-invasive markers of ureteropelvic junction obstruction
Authors: Stephane Decramer
Jean-Loup Bascands
Joost P. Schanstra
Publication date: 01-10-2007
Publisher: Springer-Verlag
Published in: World Journal of Urology / Issue 5/2007
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-007-0201-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Non-invasive markers of ureteropelvic junction obstruction

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2007

Protective role of erythropoietin during testicular torsion of the rats

Nephron sparing surgery for renal cell carcinoma in a solitary kidney

Study on enhancement of fibronectin-mediated bacillus Calmette-Guérin attachment to urinary bladder wall in rabbits

Mass spectrometry based proteomics in urine biomarker discovery

Urinary biomarkers of IgA nephropathy and other IgA-associated renal diseases

Prospective evaluation of candidate urine and cell markers in patients with interstitial cystitis enrolled in a randomized clinical trial of Bacillus Calmette Guerin (BCG)